In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.
Pathway Genomics, a company that has been in the personalized medicine business for about 7 years now, has gained the FDA’s attention for their direct-to-consumer (DTC) cancer screening test in high-risk individuals. According to the FDA, the company’s product, CancerIntercept Detect, has not undergone regulatory clearance as a “device” and could harm public health.
CancerIntercept Detect, the company’s website says, has been developed for individuals who are at risk for known hereditary cancer, have a family history of cancer, whose lifestyle choices may increase their risk for cancer, or who may have had environmental exposure to cancer causing agents. The company does claim to have a College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) accreditation.
In a letter to Pathway Genomics’ CEO Jim Plante, the FDA states that under the DTC model, Pathway is shipping blood collection tubes—classified as a medical device—for use with CancerIntercept Detect, without having submitted the tubes for FDA approval, clearance, or listing. The letter also cites the lack of clinical validation for this particular test as a screening tool for early detection of cancer in high-risk individuals. The letter goes on to state that the FDA would like to discuss with the company their validation strategy as well as evaluate data on clinical sensitivity and specificity of the test.
This is not the first time that the company has received push-back from the FDA. Back in 2010, a similar letter was sent to the company demanding justification for why their spit kit, which they had planned to market in collaboration with Walgreens, had not been FDA approved.
The DTC genetic testing industry has experienced a lot of turbulence—23andMe Inc being a prime example. In 2013, the company was prevented by the FDA from selling tests that detect disease risks, but early this year, 23andMe’s DTC test to screen for carriers of Bloom Syndrome was granted clearance. “The FDA believes that in many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information. Today’s authorization and accompanying classification, along with FDA’s intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers,” the FDA had said at the time.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More